351 related articles for article (PubMed ID: 27800032)
1. Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies.
Lousberg L; Collignon J; Jerusalem G
Ther Adv Med Oncol; 2016 Nov; 8(6):429-449. PubMed ID: 27800032
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
3. Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer.
Pegram M; Pietras R; Dang CT; Murthy R; Bachelot T; Janni W; Sharma P; Hamilton E; Saura C
Ther Adv Med Oncol; 2023; 15():17588359231187201. PubMed ID: 37576607
[TBL] [Abstract][Full Text] [Related]
4. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer.
Ferrando-Díez A; Felip E; Pous A; Bergamino Sirven M; Margelí M
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884366
[TBL] [Abstract][Full Text] [Related]
6. Overcoming endocrine resistance in hormone receptor-positive breast cancer.
AlFakeeh A; Brezden-Masley C
Curr Oncol; 2018 Jun; 25(Suppl 1):S18-S27. PubMed ID: 29910644
[TBL] [Abstract][Full Text] [Related]
7. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
Brufsky AM; Dickler MN
Oncologist; 2018 May; 23(5):528-539. PubMed ID: 29352052
[TBL] [Abstract][Full Text] [Related]
8. Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Harbeck N
Breast; 2015 Nov; 24 Suppl 2():S44-8. PubMed ID: 26321480
[TBL] [Abstract][Full Text] [Related]
9. Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications.
Giuliano M; Trivedi MV; Schiff R
Breast Care (Basel); 2013 Aug; 8(4):256-62. PubMed ID: 24415978
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature.
Thanopoulou E; Khader L; Caira M; Wardley A; Ettl J; Miglietta F; Neven P; Guarneri V
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33182657
[TBL] [Abstract][Full Text] [Related]
11. Is There a Benefit of HER2-Positive Breast Cancer Subtype Determination in Clinical Practice?
Kolářová I; Vaňásek J; Odrážka K; Dušek L; Šinkorová Z; Hlávka A; Štuk J; Stejskal J; Dvořáková D; Sákra L; Mergancová J; Vilasová Z
Klin Onkol; 2019; 32(1):25-30. PubMed ID: 30764626
[TBL] [Abstract][Full Text] [Related]
12. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
13. Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.
Larionov AA
Front Oncol; 2018; 8():89. PubMed ID: 29670855
[TBL] [Abstract][Full Text] [Related]
14. Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
Collins D; Jacob W; Cejalvo JM; Ceppi M; James I; Hasmann M; Crown J; Cervantes A; Weisser M; Bossenmaier B
PLoS One; 2017; 12(5):e0177331. PubMed ID: 28493933
[TBL] [Abstract][Full Text] [Related]
15. Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going.
Schettini F; Buono G; Cardalesi C; Desideri I; De Placido S; Del Mastro L
Cancer Treat Rev; 2016 May; 46():20-6. PubMed ID: 27057657
[TBL] [Abstract][Full Text] [Related]
16. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
17. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer.
Zhao M; Ramaswamy B
World J Clin Oncol; 2014 Aug; 5(3):248-62. PubMed ID: 25114842
[TBL] [Abstract][Full Text] [Related]
19. Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Mehta A; Tripathy D
Breast; 2014 Feb; 23(1):2-9. PubMed ID: 24176518
[TBL] [Abstract][Full Text] [Related]
20. Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.
Brandão M; Pondé NF; Poggio F; Kotecki N; Salis M; Lambertini M; de Azambuja E
Expert Rev Anticancer Ther; 2018 Jul; 18(7):629-649. PubMed ID: 29781317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
